Pharmaceuticals

Novo Nordisk AS

Medpal AI Launches New GLP-1 Sub-brand, Expects Novo Nordisk Oral Wegovy Approval in UK This Summer

Novo Nordisk to Unveil New Data on Semaglutide for Liver Disease Treatment

Novo Nordisk Initiates AMAZE 8 Clinical Trial to Test New Weight-Loss Drug Against Semaglutide

Novo Nordisk Advances New Cagrilintide Study, Boosting Competition in Obesity Treatment

Dr. Reddy's launches generic version of Novo Nordisk's Ozempic in Canada

Novo Nordisk plans to launch high-dose Wegovy in South Korea, competing with Eli Lilly in the obesity treatment market

French Regulators Fine Novo Nordisk and Lilly Over GLP-1 Campaigns

NVO Gains Competitive Insight from New Study Approvals

Novo Nordisk to Present New Analysis of Semaglutide ESSENCE Trial for MASH at 2026 EASL

Analysts Revise Novo Nordisk Price Targets Upwards Post-Q1 Earnings

Novo Nordisk Updates Its AMAZE 12 Phase 3 Trial for Next Wave in Obesity Maintenance Drugs

Novo Nordisk will host a Capital Markets Day on September 21, 2026

Two Pharma Companies Now Own Nearly 100% of GLP-1 Citations Inside ChatGPT, Claude and Perplexity, New 5W Index Finds

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Lexaria Gains Ethics Approval for Study Comparing its Semaglutide Formulation to Novo Nordisk's Wegovy

Novo Nordisk to Hold Information Meeting

Investment firm Truffle explains its rationale for recently buying and selling Novo Nordisk stock

Novo Nordisk provides an update on its share repurchase program

Novo Nordisk to hold R&D investor event at the American Diabetes Association (ADA) 2026 meeting

Novo Nordisk Launches 15 Billion DKK Share Buyback Plan

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

Micware

BiomX

MetaVia

MicroAlgo

Tradr 2X Long XNDU Daily ETF

Novo Nordisk A/S (NVO.US) Q1 2026 Earnings Conference Call

Novo Nordisk A/S (NVO.US) Q4 2025 Earnings Conference Call

Novo Nordisk A/S (NVO.US) Q3 2025 Earnings Conference Call

Novo Nordisk A/S (NVO.US) Q2 2025 Earnings Conference Call

Novo Nordisk A/S (NVO.US) 2024 Full Year Performance Conference Call

Novo Nordisk A/S (NVO.US) Q3 2024 Earnings Conference Call

ARKG

NVOX

The 2026 Milliman Medical Index reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase—the highest in over a decade. Key drivers include a 14.8% rise in pharmacy costs, influenced by GLP-1 drugs, and a 7.5% increase in outpatient facility costs. The report highlights the role of AI in optimizing billing processes, contributing to this significant cost growth.

- The Milliman Medical Index for 2026 reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase, the highest in over a decade.  
- Contributing factors include a 14.8% rise in pharmacy costs driven by GLP-1 drugs and high-cost specialty medications, alongside a 7.5% increase in outpatient facility costs.  
- Additionally, the introduction of artificial intelligence in billing processes is noted as a significant new factor in these rising costs.

MorningStar

Eli Lilly

Ark Genomic Revolution ETF

SPDR S&P Health

iShares Global Healthcare

Defiance Daily Target 2X Long LLY ETF

Invesco Biotechnology & Genome ETF

Direxion Daily LLY Bull 2X Shares

Direxion Daily LLY Bear 1X Shares

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Defiance Daily Target 2X Long NVO ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR Pharmac

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VG Health

iShares US Pharma

Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026

Novo Nordisk presented new data on semaglutide (Wegovy) at the EASL 2026 congress, highlighting its liver safety and efficacy in chronic liver disease, particularly for patients with Metabolic Dysfunction associated Steatohepatitis (MASH). The findings suggest potential broader applications for Wegovy beyond obesity and diabetes, especially for Japanese patients and menopausal women. Investors are keen to see how these results influence the company's narrative and market potential, while also considering associated risks.

Simplywall

Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors

The CDSCO has instructed states and UTs to monitor promotional activities for GLP-1 weight-loss drugs like semaglutide, following a ban on promotional activities for prescription-only therapies. The organization is enforcing compliance through audits and inspections, addressing illegal distribution and misuse. With the patent expiration of semaglutide, over 25 generic versions have emerged, prompting companies to launch multimedia campaigns focused on obesity awareness, as direct advertising is prohibited.

Business Standard

CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs

HBM HOLDINGS-Bannounced preclinical data for LET003, a monoclonal antibody for obesity treatment developed using AI. The results indicate LET003 has superior pharmacokinetics compared to competitors and, when combined with semaglutide, enhances fat reduction while preserving lean mass. At lower doses, it matches the effects of higher-dose bimagrumab in promoting lean mass gain, suggesting its potential as a Best-in-Class obesity therapy.

AASTOCKS News

HBM HOLDINGS-B

HBM HOLDINGS-B  Discloses Preclinical Data of AI Candidate Drug for Obesity Treatment

Wall Street Zen upgraded Novo Nordisk A/S from a 'hold' to a 'buy' rating. This follows mixed ratings from other brokerages, with some downgrading the stock. Currently, Novo Nordisk has an average rating of 'Hold' and a consensus price target of $65.56. The stock opened at $44.71, with a market cap of $199.63 billion and a P/E ratio of 10.50. Recent earnings showed $1.03 EPS and $10.85 billion in revenue.

Market Beat

Goldman Sachs

Hims & Hers Health

Franklin Resources

T. Rowe Price

GS Hldg R

Novo Nordisk A/S (NYSE:NVO) Upgraded at Wall Street Zen

OMER

Omeros Corporation's Q1 earnings call highlighted the successful U.S. launch of YARTEMLEA, generating $11.1 million in gross revenue. The company reported a strengthened balance sheet with $135.3 million in cash and a significant deal with Novo Nordisk worth up to $2.1 billion. Despite an adjusted net loss of $17.1 million, management expects YARTEMLEA to drive positive cash flow within 18 months. The stock has declined 38.5% since year-end 2025, raising concerns amid ongoing debt obligations.

Tip Ranks

Omeros

Omeros Earnings Call: YARTEMLEA Launch Drives New Phase

Novo Nordisk (NOVO_B): oral Wegovy trial ECO2026/OASIS4 — early responders (≈33%) lost 13.2% at 4 months, 21.6% at 64 weeks; overall treatment 17% vs placebo 2.7%.12Novo Nordisk (NOVO_B) and Rexall partner to deliver Ozempic and Wegovy to Canadian patients' homes, offering home delivery, in-store pricing and patient support—key operational updates for traders.3

TradingView

Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada

Novo Nordisk AS(NVO.US)